Although KRAS mutations play a major role during PAC tumorigenesis, there remains an unmet need for effective treatment for this lethal disease and more novel therapeutics are eagerly needed if NGS could identify valid and corresponding biomarkers. This evidence concerns the gene KRAS and gonorrhea.